Abstract
Objective We aimed to evaluate the performance of a cell free DNA (cfDNA) assay that uses next generation sequencing (NGS) with quantitative counting templates (QCT) for the clinical detection of the fetal RhD genotype in a diverse RhD-negative pregnant population in the United States (US).
Study Design This retrospective cohort study was conducted in four US healthcare centers. The same NGS QCT cfDNA fetal RhD assay was offered to non-alloimmunized, RhD-negative pregnant individuals as part of clinical care. Rh immune globulin (RhIG) was administered at the discretion of the provider. The assay’s sensitivity, specificity, and accuracy were calculated considering the neonatal RhD serology results.
Results A total of 401 non-alloimunized RhD-negative pregnancies were included in the analysis. The D antigen cfDNA result was 100% concordant with the neonatal serology, resulting in 100% sensitivity and positive predictive value and (both 95% CI: 98.6%-100%) 100% specificity and negative predictive value (both 95% CI: 97.4%-100%). There were 10 pregnancies where the cfDNA analysis identified a non-RHD gene deletion, including RhDΨ (n=5) and RHD-CE-D hybrid variants (n=5). A total of 616 doses of RhIG were administered. Even though the study occurred prior to the current RhIG shortage and the recent American College (ACOG) advisory change, there was a marked decrease in the use of antenatal RhIG in pregnancies when cfDNA results indicated an RhD-negative fetus, indicating providers were using the results to guide pregnancy management.
Conclusion This cfDNA analysis via NGS for detecting fetal RhD status is highly accurate with no false positive or false negative results in 401 racial and ethnically diverse pregnancies with 100% follow up of all live births. Our data support implementing this assay for the routine management of non-alloimmunized RhD-negative individuals. This approach will result in more efficient and targeted prenatal care with administration of RhIG only when medically indicated.
Competing Interest Statement
Dr. Samir Ahuja is a paid consultant from BillionToOne, Inc. Julia Wynn is an employee of BillionToOne, Inc. and has stock options in the company. Drs. Jenny Wiggins-Smith, J. Bret Bryant, J. Kris Citty, J. Kyle Citty and Samir Ahuja received funding for this research project from BillionToOne, Inc.
Funding Statement
Participating clinical sites received research funding from the sponsor of the study, BillionToOne Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participating institutions and the sponsor site received approved by the WCG IRB (IRB#: 20234135). The study was exempted from patient consent as it was a retrospective study of medical records from clinical care.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This study was sponsored by BillionToOne, Inc.and participating clinical sites received research funding from BillionToOne to conduct the study.
Conflict of Interest: Dr. Samir Ahuja is a paid consultant from BillionToOne, Inc. Julia Wynn is an employee of BillionToOne, Inc. and has stock options in the company. Drs. Jenny Wiggins-Smith, J. Bret Bryant, J. Kris Citty, J. Kyle Citty and Samir Ahuja received funding for this research project from BillionToOne, Inc.
Precis: cfDNA analysis via NGS is 100% accurate in detecting fetal RhD status in 401 racial and ethnically diverse pregnancies with 100% follow up of all live births.
The manuscript has been peer reviewed and edits have been made to clarify peer review questions. Analysis and conclusions have not changed.
Data Availability
A complete set of anonymized data is available on request from the corresponding author.
